Roles of Trained Immunity in the Pathogenesis of Cholangiopathies: A Therapeutic Target
Chao Yan, Stephane Koda, Jing Wu, Bei‐Bei Zhang, Qian Yu, Mihai G. Netea, Ren‐Xian Tang, Kui‐Yang Zheng – 28 May 2020
Chao Yan, Stephane Koda, Jing Wu, Bei‐Bei Zhang, Qian Yu, Mihai G. Netea, Ren‐Xian Tang, Kui‐Yang Zheng – 28 May 2020
Michael L. Volk – 28 May 2020
Seonghwan Hwang, Xiaolin Wang, Robim M. Rodrigues, Jing Ma, Yong He, Wonhyo Seo, Seol Hee Park, Seung‐Jin Kim, Dechun Feng, Bin Gao – 28 May 2020
Zoe Hall, Davide Chiarugi, Evelina Charidemou, Jack Leslie, Emma Scott, Luca Pellegrinet, Michael Allison, Gabriele Mocciaro, Quentin M. Anstee, Gerard I. Evan, Matthew Hoare, Antonio Vidal‐Puig, Fiona Oakley, Michele Vacca, Julian L. Griffin – 27 May 2020
Natalie M. Bath, Glen Leverson, David P. Al‐Adra, Anthony M. D’Alessandro, Joshua D. Mezrich, David P. Foley – 26 May 2020 – The acceptable threshold remains unknown for the percentage of macrosteatosis (MaS) and microsteatosis (MiS) to yield optimal outcomes after donation after circulatory death (DCD) liver transplantation (LT). The purpose of this analysis was to determine the impact of donor liver MaS and MiS on DCD LT outcomes.
Binita M. Kamath, Cathie Spino, Richard McLain, John C. Magee, Emily M. Fredericks, Kenneth D. Setchell, Alexander Miethke, Jean P. Molleston, Cara L. Mack, Robert H. Squires, Estella M. Alonso, Karen F. Murray, Kathleen M. Loomes, M. Kyle Jensen, Saul J. Karpen, Philip Rosenthal, Danny Thomas, Ronald J. Sokol, Benjamin L. Shneider, for the Childhood Liver Disease Research Network (ChiLDReN) – 26 May 2020 – Pruritus is a debilitating symptom for patients with Alagille syndrome (ALGS).
Stuart C. Gordon, Nandita Kachru, Emily Parker, Stephanie Korrer, A. Burak Ozbay, Robert J. Wong – 26 May 2020 – Limited evidence exists on the clinical and economic burden of advanced fibrosis in patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) due to the invasiveness of liver biopsies for accurately staging liver disease. The fibrosis‐4 (FIB‐4) score allows for noninvasive assessment of liver fibrosis by using clinical and laboratory data alone.
Jordan L. Smith, Tomás C. Rodríguez, Haiwei Mou, Suet‐Yan Kwan, Henry Pratt, Xiao‐Ou Zhang, Yueying Cao, Shunqing Liang, Deniz M. Ozata, Tianxiong Yu, Qiangzong Yin, Max Hazeltine, Zhiping Weng, Erik J. Sontheimer, Wen Xue – 26 May 2020
Benjamin Maasoumy, Anna Maria Geretti, André Frontzek, Harrison Austin, Gudrun Aretzweiler, Monica Garcia‐Álvarez, Susanne Leuchter, Christian O. Simon, Ed G. Marins, Jesse A. Canchola, Markus Cornberg, Rafael Delgado, Heiner Wedemeyer – 26 May 2020 – Despite effective hepatitis B virus (HBV)‐DNA suppression, HBV RNA can circulate in patients receiving nucleoside/nucleotide analogues (NAs).
Asako Murayama, Norie Yamada, Yoshiki Osaki, Masaaki Shiina, Hussein Hassan Aly, Masashi Iwamoto, Senko Tsukuda, Koichi Watashi, Mami Matsuda, Ryosuke Suzuki, Tomohisa Tanaka, Kohji Moriishi, Tetsuro Suzuki, Hironori Nishitsuji, Masaya Sugiyama, Masashi Mizokami, Kunitada Shimotohno, Takaji Wakita, Masamichi Muramatsu, T. Jake Liang, Takanobu Kato – 23 May 2020